Daniel Vasquez1,2, Melissa Sierra Castrillón3,4, Manuela Gomez Vega5,4, Clara Gomez Henck5, David Aguillon5,4, Elkin Garcia-Cifuentes5,6,7, Alberto Jaramillo-Jimenez5,4,8, Juan Esteban Velez5, Lucia Madrigal5, Francisco Lopera5. 1. Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. danielvasquezb96@gmail.com. 2. Grupo de Investigación en Epidemiología y Bioestadística, Universidad CES, Medellín, Colombia. danielvasquezb96@gmail.com. 3. Departamento de Psicología, Facultad de Ciencias Sociales y Humanas, Universidad de Antioquia, Medellín, Colombia. 4. Grupo Neuropsicología y Conducta, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. 5. Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. 6. Semillero de Neurociencias y Envejecimiento, Facultad de Medicina, Instituto de Envejecimiento, Pontificia Universidad Javeriana, Bogotá, Colombia. 7. Unidad de Neurología, Hospital Universitario San Ignacio, Bogotá, Colombia. 8. Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway.
Abstract
PURPOSE: The present study aims to explore the association between the quality of life (QoL) score and the clinical and sociodemographic variables in patients with the PSEN1-E280A mutation. We also seek to evaluate the differences between the QoL reported by the patients (P-QoL) and the scores reported by the caregivers (C-QoL). METHODS: An analysis of 75 patients with the PSEN1-E280A mutation with mild cognitive impairment and dementia was performed. We used the Quality of Life in Alzheimer Disease (QoL-AD) survey to evaluate QoL as an outcome and evaluated its association with sociodemographic, lifestyle, clinical, and past medical history variables. RESULTS: The largest difference in the median of the QoL-AD score was in those who needed help to eat, those with moderate or severe dementia, those classified as frail or pre-frail, those with moderate social risk, and those with depression. Also, C-QoL was lower than the P-QoL, and the QoL-AD of individuals with severe dementia was lower than for milder forms of the disease. Not needing help to eat, not having a stressful situation in the past 3 months, and the years of education were positively correlated with QoL-AD in the linear model. CONCLUSION: As studies in similar populations with AD, factors with more impact on QoL are those related to loss of functionality and independence. These factors are also associated with variables related to the current literature with the burden of the disease for the caregivers.
PURPOSE: The present study aims to explore the association between the quality of life (QoL) score and the clinical and sociodemographic variables in patients with the PSEN1-E280A mutation. We also seek to evaluate the differences between the QoL reported by the patients (P-QoL) and the scores reported by the caregivers (C-QoL). METHODS: An analysis of 75 patients with the PSEN1-E280A mutation with mild cognitive impairment and dementia was performed. We used the Quality of Life in Alzheimer Disease (QoL-AD) survey to evaluate QoL as an outcome and evaluated its association with sociodemographic, lifestyle, clinical, and past medical history variables. RESULTS: The largest difference in the median of the QoL-AD score was in those who needed help to eat, those with moderate or severe dementia, those classified as frail or pre-frail, those with moderate social risk, and those with depression. Also, C-QoL was lower than the P-QoL, and the QoL-AD of individuals with severe dementia was lower than for milder forms of the disease. Not needing help to eat, not having a stressful situation in the past 3 months, and the years of education were positively correlated with QoL-AD in the linear model. CONCLUSION: As studies in similar populations with AD, factors with more impact on QoL are those related to loss of functionality and independence. These factors are also associated with variables related to the current literature with the burden of the disease for the caregivers.
Authors: Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Carlos O Weiss; Ravi Varadhan; Milo A Puhan; Andrew Vickers; Karen Bandeen-Roche; Cynthia M Boyd; David M Kent Journal: J Gen Intern Med Date: 2014-01-18 Impact factor: 5.128
Authors: C A Lemere; F Lopera; K S Kosik; C L Lendon; J Ossa; T C Saido; H Yamaguchi; A Ruiz; A Martinez; L Madrigal; L Hincapie; J C Arango; D C Anthony; E H Koo; A M Goate; D J Selkoe; J C Arango Journal: Nat Med Date: 1996-10 Impact factor: 53.440
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566